Posts by: Magdalena Kegel

Magdalena Kegel

Magdalena is a writer with a passion for bridging the gap between the people performing research, and those who want or need to understand it. She writes about medical science and drug discovery. She holds an MS in Pharmaceutical Bioscience and a PhD — spanning the fields of psychiatry, immunology, and neuropharmacology — from Karolinska Institutet in Sweden.

May 9, 2017

Pfizer’s Xeljanz Reduced Nail Psoriasis in Phase 3 Trials of Plaque Disease

News

Pfizer’s rheumatoid arthritis drug Xeljanz (tofacitinib) was effective against nail psoriasis in patients with plaque disease, according to data from two Phase 3 clinical trials. The data further expands the ... Read more

September 2, 2016September 2, 2016

Taltz Seen as Effective Treatment for Psoriasis Arthritis in Phase 3 Trial

News

Results from a Phase 3 registered clinical trial have demonstrated that Taltz (ixekizumab) improves disease activity and physical function in patients with psoriasis arthritis. The study, “Ixekizumab, an interleukin-17A specific monoclonal antibody, ... Read more

July 22, 2016July 22, 2016

Erythrodermic Psoriasis Drug Review Calls for Guideline Update, Biologic Meds Included

News

Researchers at the University of California, Los Angeles recently provided a research review concerning treatment of erythrodermic psoriasis, a rare but severe version of common plaque psoriasis that effects at least 75% of the body. The ... Read more

July 19, 2016

Review of Mental Health Problems in Psoriasis Patients Emphasizes Inflammatory Mechanisms

News

Reviewing published studies of the connection between psoriasis and mental health conditions, researchers in Portugal noted that the link is likely maintained by cascades of inflammatory factors triggered by chronic ... Read more